Clinical trials of its Felix sperm separation device for IVF clinics are now 90 per cent complete, according to reproductive technology specialist Memphasys, with the company also sharing that it now anticipates “entering larger markets earlier than previously expected” following a decision to pursue CE mark registration. In a statement on Thursday, the company told…
ASX-listed reproductive biotechnology company Memphasys has announced results showing “clear benefits” of its Felix technology versus two widely used technologies in a Japanese trial, with results from a larger-scale trial expected to be shared in late-2024. According to an ASX statement from the company on Monday, the Felix System (pictured) outperformed a sperm preparation method…
Reproductive technology company Memphasys has announced findings from a trial at a stud farm of its semen storage and transport device in November, which will lead to further work on medium and operational improvements of the AI-Port product. In an ASX statement on Thursday, the company said the trial at the Hunter region, NSW site…
Reproductive health technology company Memphasys has announced the first order of Felix System products placed by Vitrolife Japan, the local subsidiary of Sweden’s Vitrolife Group. Memphasys said on Monday that the order was for 150 Felix System cartridges, to be supplied to five key opinion leader (KOL) clinics in Japan. Felix is described as using…
Reproductive biotechnology company Memphasys is racking up expert opinion backing the efficacy of its Felix device for improving the outcomes of IVF procedures. Male infertility is a big factor in failure of IVF treatments, with sperm quality rather than quantity the key issue. The Felix device uses an electric force and polymer membranes to separate…
Bio-separation company Memphasys has received a $1.29 million tax rebate under the R&D tax incentive scheme. The payment is a refundable tax offset of eligible expenses on research and development. The company is developing the Felix device, an instrument used in in vitro fertilisation that separates high quality sperm from a semen sample, improving the…
Medical technology company Memphasys’ Felix medical device to boost success in IVF procedures is undergoing trial by key opinion leaders internationally prior to commercial sale expected later this year. The device (pictured) which selects the best human sperm to be used while discarding the rest is undergoing trial in Japan, India, Canada the USA, Iran…
Medical technology company Memphasys plans its first commercial sales of its unique Felix medical device to boost success in IVF procedures in the second half of 2020. The Sydney company told investors in a market update that its automated, non-DNA damaging lab instrument for sperm separation was undergoing assessment by a series of key opinion…
ARE receives $5m grant for rare earths development Australian Rare Earths has received a $5 million grant from the federal government’s International Partnerships in Critical Minerals Program. The funding will support additional metallurgical test work, completion of a pre-feasibility study and building/operating a demonstration plant at the company’s Koppamurra project, a frontier ionic clay rare…
Codan completes the acquisition of Kägwerks Communications and metal detection manufacturer Codan, through its wholly owned subsidiary, Codan US Inc, has completed the acquisition of 100 percent of US-based organisation SKT2 LLC dba Kägwerks (Kägwerks). Kägwerks is a leader in tactical operator-worn networking communications technologies that enable connectivity and integrated secure networking in a military…
